Tandem Diabetes Care (Nasdaq:TNDM) shares are down today on fourth-quarter results that came up shy of the consensus forecast. Shares of TNDM were down more than 6% to $37.28 apiece by midday trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up more than 8%. Yesterday evening, the […]
Wall Street Beat
West Pharmaceutical stock skyrockets on Street-beating Q4
West Pharmaceutical Services (NYSE:WST) shares received a massive boost today on fourth-quarter results that beat the consensus forecast. Shares of WST rose 15.5% at $322.53 apiece in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 10.1%. The Exton, Pennsylvania-based drug delivery device maker […]
Embecta stock soars on Street-beating Q4, raised 2023 guidance
Embecta (Nasdaq:EMBC) shares received a boost today on fourth-quarter results that came in well ahead of the consensus forecast. Shares of EMBC ticked up 7.9% at $30.67 apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 11.3%. Wall Street’s positive reaction to […]
Dexcom stock rises after hours on Street-beating Q4
Dexcom (Nasdaq:DXCM) shares ticked up after the market closed today on fourth-quarter results that topped the consensus forecast. Shares of DXCM rose 2.2% at $109.61 apiece after hours. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 10.1%. The San Diego-based continuous glucose monitor […]
Tandem Diabetes Care expects double-digit revenue growth in 2023
Tandem Diabetes Care (Nasdaq:TNDM) announced preliminary fourth-quarter results and offered expectations for the coming year. San Diego-based Tandem expects sales to total $221 million, coming in $11 million higher than the same quarter last year. Wall Street analysts expected $221.6 million in revenues. However, the automated insulin delivery technology developer noted that its adjusted sales […]
Dexcom appoints former J&J exec as CCO, sets 2023 guidance
Dexcom (Nasdaq:DXCM) announced today that it appointed Teri Lawver to its newly created role of chief commercial officer (CCO). Lawver’s position oversees the global commercial organization at the continuous glucose monitoring (CGM) technology developer. She holds responsibility for global sales, marketing and customer experience. Before joining San Diego–based Dexcom, Lawver spent two decades in a […]
The 10 biggest diabetes tech stories from 2022
2022 represented a landmark year for next-generation diabetes tech. Here are the biggest stories from the past year. Some companies picked up major regulatory nods. Others experienced major regulatory setbacks. Partnerships were formed and ended, while mergers and acquisitions came and went. There were many stories to choose from in the world of diabetes tech, […]
Embecta stock slides on mixed Q4 results
Embecta (Nasdaq:EMBC) shares dipped today on fourth-quarter results that came in mixed compared to the consensus forecast. EEMBC shares fell more than 12% to $29.73 apiece in morning trading. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up more than 4%. The Parsippany, New Jersey-based company posted losses […]
Analysts remain neutral on Embecta, await insulin patch pump developments
BTIG analysts maintained their neutral rating for Embecta (Nasdaq:EMBC) ahead of the company’s fourth-quarter earnings report next week. Embecta, the BD diabetes spinoff, reports its fourth-quarter earnings on Tuesday, Dec. 20. Analysts Marie Thibault and Sam Eiber also expect 2023 guidance to come from management then. The analysts mainly expect the patch pump market to […]
Boston Scientific to acquire majority stake in interventional tech developer Acotec
Boston Scientific (NYSE:BSX) announced that it intends to make a partial offer to acquire a majority stake in Acotec. Marlborough, Massachusetts-based Boston Scientific’s offer could add up to a maximum of 65% of Acotec’s shares. Its proposed price totals HK$20 per share. That amounts to approximately $523 million for the 65% stake at current exchange […]
